Selected Science
Hypercholesterolemia &
Lipid-Lowering Treatment

Methodological challenges: target trial emulation for PCSK9 inhibitor timing post-MI

To assess whether the clone-censor-weight method can estimate the effectiveness of early vs delayed PCSK9 inhibitor initiation after myocardial infarction.

Early ezetimibe initiation after MI protects against cardiovascular outcomes

To compare cardiovascular outcomes in patients receiving early combination lipid-lowering therapy vs delayed or no ezetimibe after MI.

Nationwide analysis of evolocumab use in Sweden and its effect on LDL-C levels

To describe real-world prescribing patterns of evolocumab and quantify its effect on LDL-C levels in clinical practice.